

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Dominquez, et al.

Serial No.: Not yet assigned

Group Art Unit No.: Not yet assigned

Filed: Herewith

Examiner:

For: SUBSTITUTED HETEROCYCLIC COMPOUNDS  
AND METHODS OF USE

Docket No.: A-837

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).


Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees, which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Please send all future correspondence to:

US Patent Operations//RVP  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

Respectfully submitted,



Richard V. Person  
Attorney/Agent for Applicant(s)  
Registration No.: 42,991  
Phone: (805) 447-3299  
Date: April 15, 2004

**EXPRESS MAIL CERTIFICATE**

\*Express Mail® mail labeling number: EV 352488349US

Date of Deposit: April 15, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Joyce Vogel

Printed Name

Signature

<b>Modified Form PTO-1449</b>  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No. <b>A-837</b>	Serial No. <b>Not Yet Assigned</b>
	Applicant <b>Dominguez, et al</b>	
	Filing Date <b>April 15, 2004</b>	Group

### U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	5,461,053	10/24/95	Boigegrain et al.			
	A2	3,946,024	3/23/76	Fleckenstein et al.			
	A3	4,011,328	3/8/77	Pinhas et al.			
	A4	4,533,666	8/6/85	Matsumoto et al.			
	A5	5,250,530	10/5/93	Giencke et al.			
	A6	5,366,982	11/22/94	Dereu et al.			
	A7	5,861,419	1/19/99	Dube et al.			
	A8	6,174,901	1/16/01	Mantlo, et al			

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	B1	WO 97/05878		PCT				
	B2	WO 97/05877		PCT				
	B3	WO 92/02513		PCT				
	B4	JP 6-135934		Japan			X	
	B5	GB 1 238 959		Great Britain				
	B6	WO 98/03484		PCT				
	B7	WO 97/16442		PCT				
	B8	GB 2 306 108		Great Britain				
	B9	EP 0 039 051		Europe				
	B10	WO 96/24584		PCT				
	B11	WO 96/03387		PCT				
	B12	EP 0 308 020		Europe				
	B13	EP 0 388 619		Europe				
	B14	WO 97/11943		Japan			X	
	B15	WO 97/04778		PCT				

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No.	A-837	Serial No.	Not Yet Assigned
	Applicant			
	Dominguez, et al			
	Filing Date	April 15, 2004	Group	

**FOREIGN PATENT DOCUMENTS****OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

C1	Florin et al., Ann. Pharmaceutiques Francaises, 43:6, 595-599 (1985) (English translation attached)
C2	Svensson et al., Drug Metabolism Reviews, 19(2), 165-194 (1988)
C3	Bundgaard, J. Med. Chem., 32(12), 2503 (1989)
C4	Dornow et al., Chem. Ber 87, pp. 985 (1954) (English translation attached)
C5	Davies et al., J. Chem. Soc., Chem. Commun., pp. 1153 (1993)
C6	Ninomiya et al., Tetrahedron, 30:2151 (1974)
C7	Firestein et al., American Journal of Pathology, Vol. 140, p. 1309 (1992)
C8	Lang et al., Endocrinology, Vol. 130, p. 43 (1992)
C9	Szalkowski et al., Endocrinology, Vol. 136, p. 1474 (1995)
C10	Wheeler et al., Journal of Labelled Compounds and Radiopharmaceuticals, Vol. XXXI, No. 4, pp. 305 (1992)
C11	Trentham et al., Journal of Experimental Medicine, Vol. 146, pp. 857 (1977)
C12	Shohami et al., J. Cereb. Blood Flow Metab., 14:615-619 (1994)
C13	Lahdevirta et al., The American J. Med., 85:289 (1988)
C14	Clouse et al., J. Immunol., 142:431-438 (1989)
C15	Maini et al., Immunological Reviews, No. 144, pp. 195-223 (1995)
C16	Davies et al., J. Chem. Soc., Perkin Trans I, pp. 1129 (1994)
C17	Liu et al., Neuroscience Letters, 164:125-128 (1993)
C18	Liu et al., Stroke, 25:1481-1488 (1994)
C19	Gilligan et al., J. Med. Chem., 35:4344-4361 (1992)
C20	Wermuth et al., J. Med. Chem., 30:239-249 (1987)
C21	Cooper et al., Clin. Exp. Immunol., Vol. 89, pp. 244 (1992)

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No.	A-837	Serial No.	Not Yet Assigned
	Applicant			
	Dominguez, et al			
	Filing Date	April 15, 2004	Group	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

C22	Grussenmeyer et al., PNAS USA, Vol. 82, pp. 7952-7954 (1985)
C23	Thompson et al., J. Org. Chem., 49:5237-5243 (1984)
C24	Berge et al., Journal of Pharmaceutical Sciences, Vol. 66, No. 1, pp. 1 (1977)
C25	Williams et al., PNAS USA, Vol. 89, pp. 2922-2926 (1992)
C26	Beutler et al., Journal of Immunology, Vol. 135, p. 3969 (1985)
C27	Folks et al., Journal of Immunology, Vol. 136, pp. 4049 (1986)
C28	Dinarello, Eur. Cytokine Netw., Vol. 5, pp. 517-531 (1994)
C29	Brahn et al., Lymphokine and Cytokine Research, Vol. 11, pp. 253 (1992)
C30	Baracos, et al., The New England Journal of Medicine, Vol. 308, p. 553 (1983)
C31	Chandrasekhar et al., Clinical Immunology and Immunopathology, Vol. 55, pp. 382-400 (1990)
C32	Ravina et al., Eur. J. Med. Chem., 20:5, pp. 475-479 (1985)
C33	Brunner et al., Eur. J. Med. Chem., Vol. 25, pp. 35 (1990)
C34	Cohen et al., J. Am. Chem. Soc., 86:725-728 (1964)
C35	Winter et al., Proc. Soc. Exp. Biol. Med., Vol. 111, pp. 544 (1962)
C36	Courtenay et al., Nature, Vol. 283, pp. 666 (1980)
C37	Swingle, Antiinflammatory Agents, Edited by Robert Scherrer and Michael Whitehouse, Vol. II, Ch. 2, pp. 33-122 (1974)
C38	Moran et al., J. Heterocyclic Chem., 23:1071 (1986)
C39	Almstrom, Just. Lieb. Ann. Chem., 400:131 (1913) (English translation attached)
C40	Knoevenagel, Chem. Ber., 21:1344 (1888) (English translation attached)
C41	Kojima et al., Bull. Chem. Soc. Jpn., Vol. 55, pp. 1454 (1982)
C42	Khalifa, Arch. Pharm. (Weinheim), 323:883-885 (1990)
C43	Ten Hoeve et al., Synthetic Communications, 24(15), 2215-2221 (1994)
C44	Mitchell et al., Synthetic Communications, 25(8), 1231-1238 (1995)
C45	Turck et al., Bull. Soc. Chim. Fr., 130:488-492 (1993) (English translation attached)

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No.	A-837	Serial No.	Not Yet Assigned
	Applicant			
	Dominguez, et al			
	Filing Date	April 15, 2004	Group	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

C46	Ravina et al., Arch. Pharm. (Weinheim), 324:455-459 (1991)
C47	Libermann et al., Soc. Chim. 117:5, pp. 1793-1798 (1959) (English translation attached)
C48	Gabriel et al., Chem. Ber., 32:395 (1899) (English translation attached)
C49	Freifelder et al., J. Am. Chem. Soc., Vol. 82, pp. 696 (1959)
C50	Curtius, J. Prakt. Chem., 50:508-530 (1894) (English translation attached)
C51	Beyaert et al., EMBO Journal 1996, vol. 15, p 1914-23.
C52	El-Rayyes and Al-Hajjar, J. Heterocycl. Chem. 21, 1473 (1984).
C53	Joosten et al, Arthritis & Rheumatism 39:797-809 (1996).
C54	Katritzky and Rachwal, J. Heterocyclic Chem. 32, 1007 (1995).
C55	Lee et al, Circulatory Shock 44:97-103 (1995).
C56	Simchen, G., Chem. Ber. 103, 389-397 (1970).
C57	Ciufolini et al., A Unified Strategy for the Synthesis of Phenanthroizidine Alkaloids: Preparation for Sterically Congested Pyridines, J. Am. Chem. Soc. 118, pp. 12082-12089, (1996)
C58	Freisen et al., 2-Pyridinyl-3(4-Methylsulfonyl) phenylpyridines: Selective and Orally Active Cyclooxygenase-2 Inhibitors, Bioorg. Med. Chem. Lett., 19(8), pp. 2777-2782
C59	Unemara et al. synthesis of the Central Heterocyclic Skeleton of an Antibiotic, A10255, Chem. Lett., pp. 1203-1204
C60	Zoltewicz et al. Inter-ring Directed Ortho Lithiation by the 2-Pyridyl Group in Bipyridines, Tetrahedron, 52(46), pp. 14469-14474

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.